156 related articles for article (PubMed ID: 37106168)
1. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs.
Zhang L; Mosquera I; Lucas E; Rol ML; Carvalho AL; Basu P;
Nat Med; 2023 May; 29(5):1135-1145. PubMed ID: 37106168
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium.
Barlow WE; Beaber EF; Geller BM; Kamineni A; Zheng Y; Haas JS; Chao CR; Rutter CM; Zauber AG; Sprague BL; Halm EA; Weaver DL; Chubak J; Doria-Rose VP; Kobrin S; Onega T; Quinn VP; Schapira MM; Tosteson ANA; Corley DA; Skinner CS; Schnall MD; Armstrong K; Wheeler CM; Silverberg MJ; Balasubramanian BA; Doubeni CA; McLerran D; Tiro JA
J Natl Cancer Inst; 2020 Mar; 112(3):238-246. PubMed ID: 31292633
[TBL] [Abstract][Full Text] [Related]
3. Assessment of organization of cervical and breast cancer screening programmes in the Latin American and the Caribbean states: The CanScreen5 framework.
Mosquera I; Barajas CB; Zhang L; Lucas E; Benitez Majano S; Maza M; Luciani S; Basu P; Carvalho AL
Cancer Med; 2023 Oct; 12(19):19935-19948. PubMed ID: 37768035
[TBL] [Abstract][Full Text] [Related]
4. Key indicators of organized cancer screening programs: Results from a Delphi study.
Csanádi M; de Kok IM; Heijnsdijk EA; Anttila A; Heinävaara S; Pitter JG; Széles G; Ivanuš U; Priaulx J; Veerus P; Senore C; Koning HJ; Vokó Z
J Med Screen; 2019 Sep; 26(3):120-126. PubMed ID: 30621498
[No Abstract] [Full Text] [Related]
5. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
Joung RH; Nelson H; Mullett TW; Kurtzman SH; Shafir S; Harris JB; Yao KA; Brajcich BC; Bilimoria KY; Cance WG
Cancer; 2022 Jun; 128(11):2119-2125. PubMed ID: 35307815
[TBL] [Abstract][Full Text] [Related]
6. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening.
Beaber EF; Kim JJ; Schapira MM; Tosteson AN; Zauber AG; Geiger AM; Kamineni A; Weaver DL; Tiro JA;
J Natl Cancer Inst; 2015 Jun; 107(6):djv120. PubMed ID: 25957378
[TBL] [Abstract][Full Text] [Related]
7. Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium.
Tosteson AN; Beaber EF; Tiro J; Kim J; McCarthy AM; Quinn VP; Doria-Rose VP; Wheeler CM; Barlow WE; Bronson M; Garcia M; Corley DA; Haas JS; Halm EA; Kamineni A; Rutter CM; Tosteson TD; Trentham-Dietz A; Weaver DL;
J Gen Intern Med; 2016 Apr; 31(4):372-9. PubMed ID: 26658934
[TBL] [Abstract][Full Text] [Related]
8. Screening for cancer in low- and middle-income countries.
Sankaranarayanan R
Ann Glob Health; 2014; 80(5):412-7. PubMed ID: 25512156
[TBL] [Abstract][Full Text] [Related]
9. The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea.
Park H; Seo SH; Park JH; Yoo SH; Keam B; Shin A
Epidemiol Health; 2022; 44():e2022053. PubMed ID: 35760396
[TBL] [Abstract][Full Text] [Related]
10. Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
Kregting LM; Olthof EMG; Breekveldt ECH; Aitken CA; Heijnsdijk EAM; Toes-Zoutendijk E; de Koning HJ; van Ravesteyn NT
Eur J Cancer; 2022 Nov; 175():180-186. PubMed ID: 36126478
[TBL] [Abstract][Full Text] [Related]
11. [The diffusion of screening programmes in Italy, year 2010].
Zappa M; Dardanoni G; Giorgi Rossi P; Grazzini G; Naldoni C; Paci E; Pirola ME; Pizzuti R; Segnan N; Zorzi M; Federici A
Epidemiol Prev; 2012; 36(6 Suppl 1):3-7. PubMed ID: 23293267
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Leveraging Social Determinants of Health to Improve Breast, Cervical, and Colorectal Cancer Screening: A Systematic Review.
Mohan G; Chattopadhyay S
JAMA Oncol; 2020 Sep; 6(9):1434-1444. PubMed ID: 32556187
[TBL] [Abstract][Full Text] [Related]
13. Breast, Cervical, and Colorectal Cancer Screening Adherence: Effect of Low Body Mass Index in Women.
Charkhchi P; Schabath MB; Carlos RC
J Womens Health (Larchmt); 2020 Jul; 29(7):996-1006. PubMed ID: 31928405
[No Abstract] [Full Text] [Related]
14. Socioeconomic and healthcare use-related determinants of cervical, breast and colorectal cancer screening practice in the French West Indies.
Menvielle G; Dugas J; Richard JB; Luce D
Eur J Cancer Prev; 2018 May; 27(3):269-273. PubMed ID: 27824663
[TBL] [Abstract][Full Text] [Related]
15. US women screen at low rates for both cervical and colorectal cancers than a single cancer: a cross-sectional population-based observational study.
Harper DM; Plegue M; Jimbo M; Sheinfeld Gorin S; Sen A
Elife; 2022 Jun; 11():. PubMed ID: 35762572
[TBL] [Abstract][Full Text] [Related]
16. Understanding the role of access in Hispanic cancer screening disparities.
Spencer JC; Noel L; Shokar NK; Pignone MP
Cancer; 2023 May; 129(10):1569-1578. PubMed ID: 36787126
[TBL] [Abstract][Full Text] [Related]
17. Associations of multimorbidity with breast, cervical, and colorectal cancer screening delivery: a cross-sectional study of a nationally representative Japanese sample.
Yamashita H; Takahashi Y; Ishizaki T; Imura H; Nakayama T
Cancer Epidemiol; 2020 Dec; 69():101798. PubMed ID: 32980753
[TBL] [Abstract][Full Text] [Related]
18. Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
Basu P; Ponti A; Anttila A; Ronco G; Senore C; Vale DB; Segnan N; Tomatis M; Soerjomataram I; Primic Žakelj M; Dillner J; Elfström KM; Lönnberg S; Sankaranarayanan R
Int J Cancer; 2018 Jan; 142(1):44-56. PubMed ID: 28940326
[TBL] [Abstract][Full Text] [Related]
19. Associations between sociodemographic factors and breast, cervical, and colorectal cancer screening in the United States.
Mondragón Márquez LI; Domínguez Bueso DL; González Ruiz LM; Liu JJ
Cancer Causes Control; 2023 Dec; 34(12):1073-1084. PubMed ID: 37486400
[TBL] [Abstract][Full Text] [Related]
20. Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST).
Priaulx J; de Koning HJ; de Kok IMCM; Széles G; McKee M
Health Policy; 2018 Nov; 122(11):1190-1197. PubMed ID: 30177278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
